MAPK1 and neoplasm: Western blot analyses of in vivo‐treated tumors revealed that treatment with osimertinib efficiently inhibited the phosphorylation of EGFR and that of its downstream molecule, ERK, in both brain tumor and subcutaneous tumor models (Fig. 4B).